This study looks to characterize 52 clinically triple negative breast cancer (TNBC) samples through evaluating the BC360 report signatures.  There were no clinical variables included in this report, so the analyses are by PAM50 and TNBC subtypes only.  Only 46 samples were used in the analysis after removing the panel standard and QC failures.